Also known as: Elrexfio, ELREXFIO
Elranatamab is a bispecific BCMA-CD3 T-cell engager monoclonal antibody marketed as Elrexfio for relapsed or refractory multiple myeloma. It is administered subcutaneously and designed to direct T-cell cytotoxicity toward BCMA-expressing myeloma cells. The drug was approved in the U.S. in 2023 with approvals in the EU and Canada later that year.
Pfizer's ELREXFIO significantly delayed disease progression in a Phase 3 trial for multiple myeloma, outperforming a standard regimen and strengthening the case for earlier use. Separately, Pfizer completed a real-world study of its lung cancer drug lorlatinib in ROS1-positive NSCLC patients.
The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.
BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
C4 Therapeutics has initiated its Phase 2 MOMENTUM trial of cemsidomide in relapsed/refractory multiple myeloma, targeting enrollment completion in Q1 2027 and a registrational dataset by 2028. The company plans a combination study with elranatamab in Q2 2026.
Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.
Cytokinetics launches MYQORZO for obstructive hypertrophic cardiomyopathy following FDA approval, while C4 Therapeutics doses first patient in Phase 2 trial of cemsidomide for relapsed/refractory multiple myeloma.
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07637578 |
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma |
RECRUITING | PHASE2 |
| NCT07382739 |
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" |
RECRUITING | PHASE2 |
| NCT07320326 |
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab |
NOT_YET_RECRUITING | |
| NCT07280013 |
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects |
RECRUITING | PHASE1 |
| NCT06997081 |
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma |
RECRUITING | PHASE2 |
| NCT06988488 |
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma |
RECRUITING | PHASE1/PHASE2 |
| NCT06974786 |
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma |
RECRUITING | PHASE2 |
| NCT06947083 |
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma |
RECRUITING | PHASE2 |
| NCT06931704 |
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) |
NOT_YET_RECRUITING | PHASE2 |
| NCT06918002 |
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients |
RECRUITING | PHASE3 |
